Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Phase 3 Study to Evaluate the Safety and Immunogenicity of mRNA Vaccines for SARS-CoV-2 Variants in Participants Aged 6 Months to < 6 Years

NCT05436834 is registered in ClinicalTrials.gov with ModernaTX, Inc. as lead sponsor.

NCT NCT05436834
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05436834 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Phase 3 Study to Evaluate the Safety and Immunogenicity of mRNA Vaccines for SARS-CoV-2 Variants in Participants Aged 6 Months to < 6 Years
Lead sponsor
ModernaTX, Inc.
Phase
Phase 3
Overall status
Completed
Start date
June 21, 2022
Completion date
October 20, 2025
Enrollment
1,807 (actual)
Sites
74

Conditions

As the registry lists them; a condition with its own page is linked.

sars-cov-2